Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
This study is currently recruiting participants.
Verified December 2011 by Medical University of Vienna
Sponsor:
Medical University of Vienna
Information provided by (Responsible Party):
Martin Burian, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01314274
First received: March 9, 2011
Last updated: December 13, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |